1. A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. NCT02130557

2. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation. NCT02181413

3. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. NCT03069352

4. A Phase 3, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT- P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma. NCT02260804

5. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled trial comparing the efficacy and safety of Polatuzumab Vedotin in combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in previously untreated patients with diffuse large B-cell lymphoma. NCT03274492

6. Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):89-97.

7. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 2022 Jan 27;386(4):351-363
. NCT03274492

8 Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia. Cancer Med. 2021 May;10(9):2946-2955 Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients with Acute Myeloid Leukemia. NCT02875093

9 A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms. Blood 2020, 136, 15-16 NCT03222609

10 Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020 Jun 11;135(24):2137-2145 A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax CoAdministered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. NCT03069352

11 A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
N Engl J Med. 2020 Mar 26;382:1219-1231 A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β)-thalassemia NCT02604433

12 A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study Eur J Cancer. 2020 Jan;124:123-130 A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Unresectable or Metastatic Pancreatic Cancer. NCT03443492

13 Oral Ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Jan 19;393(10168):253-264 A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant. NCT02181413

14 Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018 Jan 20;36(3):231-237 A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. NCT02130557

17 A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients Sci Rep. 2017 Sep 12;7(1):11253 Phase II Study of ADI-PEG 20 Plus Low Dose Cytarabine in relapse/refractory Acute Myeloid Leukemia. NCT01910012

18 Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy Journal of Clinical Oncology 2014, 34 (4_suppl), 134-134 Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients NCT 01389583